Drs Adam Christman and Christopher Byers highlight recent FIP treatment advancements
In June 2024, compounded GS-441524 became available by veterinary prescription for veterinary offices as well as individual patients permitted in the United States, giving veterinarians in the United States access to a feline infectious peritonitis (FIP) oral treatment. The compounded oral medication has come from an exclusive partnership between Stokes Pharmacy and Bova Group and is the first legal FIP treatment in the US.1
On this week's episode of The Vet Blast Podcast presented by dvm360, our host Adam Christman, DVM, MBA, welcomed guest Christopher G. Byers, DVM, DACVECC, DACVIM (SAIM), CVJ, to discuss recent advancements in FIP treatment, emphasizing the importance of accurate diagnosis, and more.
Below is a partial transcript
Christopher G. Byers, DVM, DACVECC, DACVIM (SAIM), CVJ: Historically, treatment of FIP has included medications like prednisolone, interferon and polyprenyl immunostimulant, and as the listeners know, these treatments have been largely unsuccessful and often resulted in euthanasia. Our colleagues in the United Kingdom and Australia have had legal access to something called GS 5734, more commonly known as remdesivir. This is a prodrug of GS 441524, with an extra chemical side chain that is supposed to improve cellular penetration. They're really lucky. They have access to both injectable and oral forms, and there are established protocols in these geographic locales for each route of administration.
In the USA, we currently have no FDA approved treatments for treatment of FIP. However, Stokes Pharmacy, a PCAB accredited compounding pharmacy, has recently established an exclusive partnership with the Bova Group to offer a US made oral treatment for FIP so American veterinarians can now manage their FIP patients with Stokes Pharmacy's compounded preparation that is supported by Bova's, unique drug formula that's been utilized in clinical research studies across the globe.
Reference